Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study
- PMID: 24700439
- DOI: 10.1136/gutjnl-2013-305506
Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study
Abstract
Objective: Endoscopic surveillance of Barrett's oesophagus (BO) provides an opportunity to detect early stage oesophageal adenocarcinoma (OAC). We sought to determine the proportion of OAC patients with a prior diagnosis of BO on a population basis and to evaluate the influence of a prior diagnosis of BO on survival, taking into account lead and length time biases.
Design: A retrospective population-based study of all OAC patients in Northern Ireland between 2003 and 2008. A prior BO diagnosis was determined by linkage to the Northern Ireland BO register. Stage distribution at diagnosis and histological grade were compared between patients with and without a prior BO diagnosis. Overall survival, using Cox models, was compared between patients with and without a prior BO diagnosis. The effect of adjusting the survival differences for histological grade and estimates of lead and length time bias was assessed.
Results: There were 716 OAC cases, 52 (7.3%) of whom had a prior BO diagnosis. Patients with a prior BO diagnosis had significantly lower tumour stage (44.2% vs. 11.1% had stage 1 or 2 disease; p<0.001), a higher rate of surgical resection (50.0% vs. 25.5%; p<0.001) and had a higher proportion of low/intermediate grade tumours (46.2% vs. 26.5%; p=0.011). A prior BO diagnosis was associated with significantly better survival (HR for death 0.39; 95% CI 0.27 to 0.58), which was minimally influenced by adjustment for age, sex and tumour grade (adjusted HR 0.44; 95% CI 0.30 to 0.64). Correction for lead time bias attenuated but did not abolish the survival benefit (HR 0.65; 95% CI 0.45 to 0.95) and further adjustment for length time bias had little effect.
Conclusions: The proportion of OAC patients with a prior diagnosis of BO is low; however, prior identification of BO is associated with an improvement in survival in OAC patients.
Keywords: BARRETT'S OESOPHAGUS; CANCER EPIDEMIOLOGY; OESOPHAGEAL CANCER.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Comment in
-
Does a prior diagnosis of Barrett's oesophagus influence risk of dying from oesophageal adenocarcinoma?Gut. 2015 Jan;64(1):5-6. doi: 10.1136/gutjnl-2014-307171. Epub 2014 Apr 28. Gut. 2015. PMID: 24777488 No abstract available.
Similar articles
-
Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.Gut. 2016 Apr;65(4):548-54. doi: 10.1136/gutjnl-2014-308802. Epub 2015 Apr 22. Gut. 2016. PMID: 25903690
-
Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus.Eur J Cancer. 2017 Apr;75:41-46. doi: 10.1016/j.ejca.2016.12.037. Epub 2017 Feb 17. Eur J Cancer. 2017. PMID: 28214656
-
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.BMJ Open. 2015 Jan 29;5(1):e006640. doi: 10.1136/bmjopen-2014-006640. BMJ Open. 2015. PMID: 25633286 Free PMC article.
-
Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients.Aliment Pharmacol Ther. 2020 Jul;52(1):20-36. doi: 10.1111/apt.15760. Epub 2020 May 26. Aliment Pharmacol Ther. 2020. PMID: 32452599 Free PMC article.
-
Epidemiology and prevention of oesophageal adenocarcinoma.Scand J Gastroenterol. 2022 Aug;57(8):891-895. doi: 10.1080/00365521.2022.2042594. Epub 2022 Mar 2. Scand J Gastroenterol. 2022. PMID: 35234549 Review.
Cited by
-
Barrett's oesophagus: how should we manage it?Frontline Gastroenterol. 2015 Apr;6(2):108-116. doi: 10.1136/flgastro-2014-100552. Epub 2015 Feb 19. Frontline Gastroenterol. 2015. PMID: 28839797 Free PMC article. Review.
-
Barrett's esophagus: diagnosis and management.Gastrointest Endosc. 2017 May;85(5):889-903. doi: 10.1016/j.gie.2017.01.007. Epub 2017 Jan 18. Gastrointest Endosc. 2017. PMID: 28109913 Free PMC article. Review. No abstract available.
-
Effects of socioeconomic status on esophageal adenocarcinoma stage at diagnosis, receipt of treatment, and survival: A population-based cohort study.PLoS One. 2017 Oct 11;12(10):e0186350. doi: 10.1371/journal.pone.0186350. eCollection 2017. PLoS One. 2017. PMID: 29020052 Free PMC article.
-
A Clinical Validation of a Diagnostic Test for Esophageal Adenocarcinoma Based on a Novel Serum Glycoprotein Biomarker Panel: PromarkerEso.Proteomes. 2025 Jun 4;13(2):23. doi: 10.3390/proteomes13020023. Proteomes. 2025. PMID: 40559996 Free PMC article.
-
Prevalence of Barrett's esophagus and performance of societal screening guidelines in an unreferred primary care population of U.S. veterans.Gastrointest Endosc. 2021 Feb;93(2):409-419.e1. doi: 10.1016/j.gie.2020.06.032. Epub 2020 Jun 19. Gastrointest Endosc. 2021. PMID: 32565183 Free PMC article.
Publication types
MeSH terms
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical